← Leaderboards
Jing Hu
University Of Pittsburgh At Pittsburgh
$4,515,395
Attributed
$4,515,395
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $510.4K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,515,395 · 5
By mechanism
R01$3,306,320 · 2
R21$743,082 · 2
K22$465,993 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Yang Liu$8,494,764
- J Peter Rubin$4,602,483
- Shikhar Uttam$1,466,219
- M. Ilyas Kamboh$33,365,358
- Christopher Mahoney$76,166
Others in their field
Top investigators on “Xenograft Model”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$97,842,001
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Samuel Singer · Sloan-Kettering Inst Can Research$23,058,247
- Larry Arthur$20,604,376
Research focus
Xenograft ModelMalignant NeoplasmsPathway InteractionsMutationSignal TransductionGeneticTissuesCellsMolecularTumor GrowthUnited StatesBiologicalRegulationPlayGrowthTumorMutantColorectal CancerCytoplasmCancer CellMediatingIn VitroCancer TherapyColon Carcinoma
Grant awards (17)
Targeting PYK2 for the treatment of PDAC$340,095
R01 · FY2024 · CA · contact PI
Targeting PYK2 for the treatment of PDAC$350,834
R01 · FY2023 · CA · contact PI
Targeting PYK2 for the treatment of PDAC$350,834
R01 · FY2022 · CA · contact PI
Targeting PYK2 for the treatment of PDAC$357,994
R01 · FY2021 · CA · contact PI
Targeting PYK2 for the treatment of PDAC$357,994
R01 · FY2020 · CA · contact PI
HDAC2 in HDAC inhibitor-based therapy for CRC$319,550
R01 · FY2016 · CA · contact PI
HDAC2 in HDAC inhibitor-based therapy for CRC$319,550
R01 · FY2015 · CA · contact PI
HDAC2 in Oncogenesis$167,475
R21 · FY2015 · CA · contact PI
HDAC2 in HDAC inhibitor-based therapy for CRC$309,711
R01 · FY2014 · CA · contact PI
HDAC2 in Oncogenesis$200,644
R21 · FY2014 · CA · contact PI
HDAC2 in HDAC inhibitor-based therapy for CRC$297,452
R01 · FY2013 · CA · contact PI
HDAC2 in HDAC inhibitor-based therapy for CRC$302,306
R01 · FY2012 · CA · contact PI
Role of Translational Control in Anti-Cancer Effects of PEITC$204,525
R21 · FY2009 · CA · contact PI
Role of Translational Control in Anti-Cancer Effects of PEITC$170,438
R21 · FY2008 · CA · contact PI
Regulation of NF-kappaB2 by TSA: Role of Acetylation$155,331
K22 · FY2007 · CA · contact PI
Regulation of NF-kappaB2 by TSA: Role of Acetylation$155,331
K22 · FY2006 · CA · contact PI
Regulation of NF-kappaB2 by TSA: Role of Acetylation$155,331
K22 · FY2005 · CA